AMERICAN ORIENTAL BIOENGINEERING, Inc. (NY:AOB)

View All ReportsStreetInsider.com Reports on AOB

Nov 16, 2009 05:35 PM After-Hours Movers 11/16: ZOOM, SPRD, LFT, SINA Higher; PSUN, ADG, SIVB, AOB, SII, TGP Lower

Nov 16, 2009 04:17 PM American Oriental Bioengineering (AOB) Posts Q3 EPS of $0.13, Misses by 4c

Nov 13, 2009 02:32 PM Trading Radar for 11/16: Lowe's (LOW), Pacific Sunwear (PSUN), Assured Guaranty (AGO), Franklin Covey (FC) Report

Oct 12, 2009 07:20 AM American Oriental (AOB) Files S-3 to Sell Up to 150M in Shelf Sale

Aug 11, 2009 08:48 AM American Oriental Bioengineering (AOB) Announces Change in Independent Public Accounting Firm

View All Press ReleasesCompany Press Releases on AOB

Nov 16, 2009 04:01PM American Oriental Bioengineering Reports Third Quarter 2009 Financial Results

Nov 10, 2009 02:00PM China Aoxing Pharmaceutical Company to Present at Brean Murray, Carret & Co. 2009 China Growth Conference

Nov 9, 2009 04:01PM American Oriental Bioengineering to Report Third Quarter 2009 Financial Results on November 16, 2009

Oct 19, 2009 08:30AM China Aoxing Pharmaceutical Company to Present at 2009 China Growth Conference of Adam Friedman Associates on October 28, 2009

Oct 14, 2009 09:30AM China Aoxing Pharmaceutical Company Reports Fiscal Year 2009 Financial Results

StreetInsider Reports on AOB by Category

• Analyst Ratings
• Mergers and Acquisitions
• Earnings
• Guidance
• Stock Buybacks
• Dividends
• Retail Sales
• Management Changes
• Insider Trades
• View More Categories

View All BlogsBlogs on AOB

Nov 22, 2009 08:03 AM China Biotech Week in Review: CROs Consolidating

Nov 18, 2009 04:06 AM American Oriental's Q3 Disappoints Again

Nov 17, 2009 02:50 PM AOB's Cash Generation Provides Backstop to Earnings Miss

Nov 16, 2009 01:55 PM Chasing Value: Ten stocks for 2010 -- Part 3

Sep 23, 2009 11:53 AM AOB's Disclosures Concerning Director Cosimo Patti Appear Incomplete

View All FilingsSEC Filings on AOB

Nov 16, 2009 05:22PM Form 10-Q AMERICAN ORIENTAL BIOENG For: Sep 30

Nov 9, 2009 05:08PM Form NT 10-Q AMERICAN ORIENTAL BIOENG For: Sep 30

Oct 9, 2009 05:12PM Form S-3 AMERICAN ORIENTAL BIOENG

View All Comments Comments on recent AOB articles

Not a very good CC
on Aug 12, 2008
at 07:42 PM Adam There seemed to be allot of nervous people and nothing really getting explained. I agree that something made me not trust them. I see no real reason for them to buy this instead of a real drug company. Is this new company they waisted all that money on related to AOB CEO?
Article: Piper Jaffray Downgrades American Oriental Bioengineering (AOB) to Neutral

Follow
on Aug 12, 2008
at 02:15 PM Great Call!!??LOL.. Pj.. should re read earnings and listen CC again.. or see a Doc..
Article: Piper Jaffray Downgrades American Oriental Bioengineering (AOB) to Neutral

James
on Aug 12, 2008
at 12:51 PM How can you not get it? Piper did call a good downgrade The big world drug companies have already learned:Its not adding more drup reps that bring in major sales, its adding a better product to your line. AOB sells basically the same things other China companies sell. How could you not get it?
Article: Piper Jaffray Downgrades American Oriental Bioengineering (AOB) to Neutral

James
on Aug 12, 2008
at 12:41 PM Deserved downgrade Something is really starting to smell with AOB. This latest action by them seems like it is being done so they can cover up a loose money trail.
Article: Piper Jaffray Downgrades American Oriental Bioengineering (AOB) to Neutral

Miller
on Aug 12, 2008
at 12:37 PM Don't get it Piper handled the failed offering several months ago, and was replace by Merrill as manager of the second offering. Sore losers. This is a new analyst for Piper who does not seem to understand the implications of this acquisition, as most acquisitions have not been understood. This history of acquisitions by AOB is that they have made very good judgments, have gained a very considerable return from them, and they know the market far better than Piper does. This acquisition will have a significant growth impact on all of AOBs businesses, increase margins and return from those, give them leverage for future acquisitions bycontrolling distribution channels, and greatly increase revenue, although margins will come down as a result of this type of business. But, net return to shareholders on the 110m should be good.
Article: Piper Jaffray Downgrades American Oriental Bioengineering (AOB) to Neutral

Comments on AOB

No comments are currently available.

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?